Ideaya Biosciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $28.96
- Today's High:
- $30.01
- Open Price:
- $29.6
- 52W Low:
- $10.6
- 52W High:
- $30.25
- Prev. Close:
- $28.95
- Volume:
- 589717
Company Statistics
- Market Cap.:
- $1.71 billion
- Book Value:
- 8.733
- Revenue TTM:
- $45.15 million
- Operating Margin TTM:
- -187.77%
- Gross Profit TTM:
- $-38605000
- Profit Margin:
- -164.25%
- Return on Assets TTM:
- -12.24%
- Return on Equity TTM:
- -19.24%
Company Profile
Ideaya Biosciences Inc had its IPO on 2019-05-23 under the ticker symbol IDYA.
The company operates in the Healthcare sector and Biotechnology industry. Ideaya Biosciences Inc has a staff strength of 116 employees.
Stock update
Shares of Ideaya Biosciences Inc opened at $29.6 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $28.96 - $30.01, and closed at $29.37.
This is a +1.45% increase from the previous day's closing price.
A total volume of 589,717 shares were traded at the close of the day’s session.
In the last one week, shares of Ideaya Biosciences Inc have slipped by -1.34%.
Ideaya Biosciences Inc's Key Ratios
Ideaya Biosciences Inc has a market cap of $1.71 billion, indicating a price to book ratio of 2.2128 and a price to sales ratio of 16.2851.
In the last 12-months Ideaya Biosciences Inc’s revenue was $45.15 million with a gross profit of $-38605000 and an EBITDA of $-82437000. The EBITDA ratio measures Ideaya Biosciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Ideaya Biosciences Inc’s operating margin was -187.77% while its return on assets stood at -12.24% with a return of equity of -19.24%.
In Q2, Ideaya Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 39.4%.
Ideaya Biosciences Inc’s PE and PEG Ratio
- Forward PE
- 4.649
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.51 per share while it has a forward price to earnings multiple of 4.649 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ideaya Biosciences Inc’s profitability.
Ideaya Biosciences Inc stock is trading at a EV to sales ratio of 8.6961 and a EV to EBITDA ratio of -8.2831. Its price to sales ratio in the trailing 12-months stood at 16.2851.
Ideaya Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $527.56 million
- Total Liabilities
- $25.34 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $884000
- Dividend Payout Ratio
- 0%
Ideaya Biosciences Inc ended 2024 with $527.56 million in total assets and $0 in total liabilities. Its intangible assets were valued at $527.56 million while shareholder equity stood at $501.61 million.
Ideaya Biosciences Inc ended 2024 with $0 in deferred long-term liabilities, $25.34 million in other current liabilities, 6000.00 in common stock, $-286969000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $102.84 million and cash and short-term investments were $510.09 million. The company’s total short-term debt was $1,961,000 while long-term debt stood at $0.
Ideaya Biosciences Inc’s total current assets stands at $501.79 million while long-term investments were $16.38 million and short-term investments were $390.87 million. Its net receivables were $160000.00 compared to accounts payable of $5.87 million and inventory worth $-16377000.00.
In 2024, Ideaya Biosciences Inc's operating cash flow was $0 while its capital expenditure stood at $884000.
Comparatively, Ideaya Biosciences Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $29.37
- 52-Week High
- $30.25
- 52-Week Low
- $10.6
- Analyst Target Price
- $33
Ideaya Biosciences Inc stock is currently trading at $29.37 per share. It touched a 52-week high of $30.25 and a 52-week low of $30.25. Analysts tracking the stock have a 12-month average target price of $33.
Its 50-day moving average was $24.69 and 200-day moving average was $19.95 The short ratio stood at 14.2 indicating a short percent outstanding of 0%.
Around 135.1% of the company’s stock are held by insiders while 8348% are held by institutions.
Frequently Asked Questions About Ideaya Biosciences Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company’s lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase II clinical trial for patients with solid tumors having methylthioadenosine phosphorylase gene deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester todevelop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase II/III study in metastatic uveal melanoma, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.